Loading...
•
Dec 31, 2023
Shattuck Labs Q4 2023 Earnings Report
Reported fourth quarter and full-year 2023 financial results and recent business highlights.
Key Takeaways
Shattuck Labs reported a net loss of $17.7 million for the fourth quarter of 2023, compared to a net loss of $25.4 million for the same period in 2022. The company's cash and cash equivalents and investments were $130.6 million as of December 31, 2023, and are expected to fund operations into 2026.
Announced positive topline data from the Phase 1A/B clinical trial of SL-172154 in combination with azacitidine in frontline Higher-Risk Myelodysplastic Syndromes and frontline TP53 mutant Acute Myeloid Leukemia patients.
Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m AML patients in the fourth quarter of 2023.
Completed enrollment and presented positive interim data from the Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.
Entered into strategic collaboration and license agreement with Ono Pharmaceutical Co., Ltd to generate novel bifunctional fusion proteins.
Shattuck Labs
Shattuck Labs
Forward Guidance
Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its operations into 2026, beyond results from its Phase 1 clinical trials of SL-172154.